Download or read book Cardiovascular Drug Development written by John Somberg and published by CRC Press. This book was released on 1998-11-04 with total page 259 pages. Available in PDF, EPUB and Kindle. Book excerpt: These multidisciplinary presentations provide information essential to devising effective drug protocols in cardiovascular drug development, facilitating the approval process. Guides researchers and developers through the government drug approval process, facilitating development, minimizing costs, and harmonizing international standards employed in the creation of vital new cardiovascular therapies! Cardiovascular Drug Development explores the delicate balance of efficacy and safety that cardiovascular therapy must achieve to gain regulatory approval discusses the search for surrogates and the need in some areas for natural history endpoints reviews optimum strategies for protocol design in the development of drugs to treat hypertension, cardiac arrhythmias, heart failure, coronary artery disease, and hypercholesterolemia and other lipid disorders compares and contrasts the varying standards of evidence for drug approval in the United States, Europe, and Asia and more! Cardiovascular Drug Development will prove to be a valuable asset for cardiologists, pharmacologists and pharmacists, regulatory affairs specialists, and directors of research and development for pharmaceutical companies.
Download or read book Frontiers in Cardiovascular Drug Discovery Volume 5 written by Atta-ur-Rahman and published by Bentham Science Publishers. This book was released on 2020-10-02 with total page 278 pages. Available in PDF, EPUB and Kindle. Book excerpt: Frontiers in Cardiovascular Drug Discovery is a book series devoted to publishing the latest advances in cardiovascular drug design and discovery. Each volume brings reviews on the biochemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships of molecules used in cardiovascular therapy. The book series should prove to be of great interest to all medicinal chemists and pharmaceutical scientists involved in preclinical and clinical research in cardiology. The fifth volume of the series covers the following topics: -The Lipid Hypothesis: From Resins to Proprotein Convertase Subtilisin/Kexin Type-9 Inhibitors -The Role of SGLT2i in the Prevention and Treatment of Heart Failure -Natural Products and Semi-Synthetic Compounds as Antithrombotics: A Review of the Last Ten Years (2009-2019) -Transient Receptor Potential Channels: Therapeutic Targets for Cardiometabolic Diseases? -Treatment of Raynaud’s Phenomenon -Traditional Medicine Based Cardiovascular Therapeutics -Cardiovascular Disease: A Systems Biology Approach
Download or read book Frontiers in Cardiovascular Drug Discovery written by Atta-ur- Rahman and published by Bentham Science Publishers. This book was released on 2011-08-11 with total page 359 pages. Available in PDF, EPUB and Kindle. Book excerpt: "Frontiers in Cardiovascular Drug Discovery" is an Ebook series devoted to publishing the latest and the most important advances in Cardiovascular drug design and discovery. Eminent scientists write contributions on all areas of rational drug design and d
Download or read book Cardiac Drug Development Guide written by Michael K. Pugsley and published by Springer Science & Business Media. This book was released on 2008-02-06 with total page 427 pages. Available in PDF, EPUB and Kindle. Book excerpt: Cardiac Drug Development Guide outlines, in detail, the therapeutics of cardiac medicine currently at the cutting edge of scientific research and development around the world. This volume integrates basic and clinical cardiac pharmacology by c- bining, for the first time, both classical and molecular aspects of therapeutic drug development. The chapters comprise a broad spectrum of therapeutic areas and hence involve a comprehensive discussion of molecular, biochemical, and electrophy- ological concepts based on years of in vitro as well as in vivo pharmacological st- ies. In addition, the latter part of the book includes comprehensive clinical cardiac chapters that describe important topics in molecular medicine. These chapters also discuss current clinical therapeutic trends in medicine and provide an evaluation of the efficacy of novel drugs in these areas. Cardiac Drug Development Guide has many distinctive and outstanding features that set it apart from other cardiac pharmacology books. This book introduces topics in an easily understandable format for researchers in many varying disciplines by integrating and thereby simplifying concepts not usually discussed across a broad range of cardiac disciplines and in a highly technical field. Each chapter not only introduces and describes the physiology, pharmacology, and pathophysiology of the disease, but also overviews the clinical implications of drug development, what stages these areas are currently in, and also reviews some of the methodologies involved in drug discovery and development. As a result, this book provides a comprehensive overview of the most advanced procedures in cardiac pharmacology today.
Download or read book Frontiers in Cardiovascular Drug Discovery Volume 6 written by M. Iqbal Choudhary and published by Bentham Science Publishers. This book was released on 2022-11-11 with total page 256 pages. Available in PDF, EPUB and Kindle. Book excerpt: Frontiers in Cardiovascular Drug Discovery is a book series devoted to publishing the latest advances in cardiovascular drug design and discovery. Each volume brings reviews on the biochemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships of molecules used in cardiovascular therapy. The book series should prove to be of great interest to all medicinal chemists and pharmaceutical scientists involved in preclinical and clinical research in cardiology. Volume 6 covers the following topics: - Cardiovascular effects of ranolazine and the scope for translational research: a current review of literature - Rho/Rho kinase signaling pathway and disease: - Hibernation or transformation? Challenges in cardiovascular drug development - New approaches in P2Y12 receptor blocker drugs use - Pathophysiological links between diabetes and cardiovascular diseases: at the biochemical and molecular levels
Download or read book Frontiers in Cardiovascular Drug Discovery written by Atta-ur-Rahman and published by Bentham Science Publishers. This book was released on 2016-11-01 with total page 406 pages. Available in PDF, EPUB and Kindle. Book excerpt: Frontiers in Cardiovascular Drug Discovery is an eBook series devoted to publishing the latest advances in cardiovascular drug design and discovery. Each volume brings reviews on the biochemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships of molecules used in cardiovascular therapy. The eBook series should prove to be of great interest to all medicinal chemists and pharmaceutical scientists involved in preclinical and clinical research in cardiology. The third volume of the series covers the following topics: - P2Y12 receptor agonists -Heart failure pharmacotherapy -Vasopressin and the cardiovascular system -Cerebral small vessel disease -Complement blocking therapeutic strategies -New antiplatelet and anticoagulating agents for gastrointestinal treatments
Download or read book Practical Considerations for Adaptive Trial Design and Implementation written by Weili He and published by Springer. This book was released on 2014-10-15 with total page 420 pages. Available in PDF, EPUB and Kindle. Book excerpt: This edited volume is a definitive text on adaptive clinical trial designs from creation and customization to utilization. As this book covers the full spectrum of topics involved in the adaptive designs arena, it will serve as a valuable reference for researchers working in industry, government and academia. The target audience is anyone involved in the planning and execution of clinical trials, in particular, statisticians, clinicians, pharmacometricians, clinical operation specialists, drug supply managers, and infrastructure providers. In spite of the increased efficiency of adaptive trials in saving costs and time, ultimately getting drugs to patients sooner, their adoption in clinical development is still relatively low. One of the chief reasons is the higher complexity of adaptive design trials as compared to traditional trials. Barriers to the use of clinical trials with adaptive features include the concerns about the integrity of study design and conduct, the risk of regulatory non-acceptance, the need for an advanced infrastructure for complex randomization and clinical supply scenarios, change management for process and behavior modifications, extensive resource requirements for the planning and design of adaptive trials and the potential to relegate key decision makings to outside entities. There have been limited publications that address these practical considerations and recommend best practices and solutions. This book fills this publication gap, providing guidance on practical considerations for adaptive trial design and implementation. The book comprises three parts: Part I focuses on practical considerations from a design perspective, whereas Part II delineates practical considerations related to the implementation of adaptive trials. Putting it all together, Part III presents four illustrative case studies ranging from description and discussion of specific adaptive trial design considerations to the logistic and regulatory issues faced in trial implementation. Bringing together the expertise of leading key opinion leaders from pharmaceutical industry, academia, and regulatory agencies, this book provides a balanced and comprehensive coverage of practical considerations for adaptive trial design and implementation.
Download or read book Drugs Looking for Diseases written by R. Vos and published by Springer Science & Business Media. This book was released on 2012-12-06 with total page 398 pages. Available in PDF, EPUB and Kindle. Book excerpt: We all know how much time, effort and money it takes to develop a new drug. Hundreds of chemical compounds have to be synthesized and thousands of different activities in biology, physiology, pharmacology, clinical investigation, management and marketing have to be initiated and coordinated. Each new drug starts a voyage of discovery through an unmapped terrain which is shrouded in mist and beset by pitfalls, as Dr. Rein Vos puts it in his absorbing inside story of the development of the beta-adrenoceptor blocking agents and the calcium antagonists. Indeed we know, for example, how long it took before the theory of Ahlquist of the alpha and beta adrenergic receptors was widely accepted. Similarly, it suffices to memorize shortly the difficulty of expanding the new concept of calcium antagonism through the national German boundaries into the world. This shows how laborious and complex pharmaceutical progress is, and we all will benefit from a deeper understanding of the process of innovative drug research.
Download or read book Cardiovascular Diseases written by Y. Robert Li and published by John Wiley & Sons. This book was released on 2015-04-06 with total page 501 pages. Available in PDF, EPUB and Kindle. Book excerpt: Written in an accessible style and consistent format, the book covers both the fundamentals and advances in the pharmacology of cardiovascular drugs, as well as their integrated applications in the management of individual cardiovascular diseases. • Integrates fundamentals and recent advances regarding cardiovascular drugs, blending basic and clinical sciences needed to effectively understand and treat cardiovascular diseases • Facilitates understanding of drug action and mechanism by covering physiology / pathophysiology and pharmacology • Includes guidelines and algorithms for pharmacotherapeutic management of cardiovascular diseases • Uses case presentations and study questions to enhance understanding of the material • Serves as a resource for pharmaceutical and medical students and researchers interested in cardiovascular issues
Download or read book Cardiovascular Safety in Drug Development and Therapeutic Use written by J. Rick Turner and published by Springer. This book was released on 2016-07-28 with total page 350 pages. Available in PDF, EPUB and Kindle. Book excerpt: At a time when the field of cardiac safety is going through important changes, this unique book provides the rationale for, and cutting-edge explanations of, new regulatory landscapes that will likely govern cardiac safety assessments globally for the foreseeable future. Exposure-response modeling is already being accepted by regulatory agencies in lieu of the traditional Thorough QT/QTc Study, and the Comprehensive in vitro Proarrhythmia Assay initiative is well under way. Developments in the field of cardiovascular safety are also described and discussed in the book. These include the search for more efficient ways to exonerate new drugs for type 2 diabetes from an unacceptable cardiovascular liability, how best to address off-target blood pressure increases induced by noncardiovascular drugs, and the continued evolution of the discipline of Cardio-oncology. “a resource that will likely serve as a standard for years to come” - Dr Jonathan Seltzer Therapeutic Innovation & Regulatory Science, 2017;51(2):180 “I have no hesitation in recommending this book as a valuable reference source” - Dr Rashmi Shah Journal for Clinical Studies, 2017;9(1):62-63
Download or read book Pathophysiology and Pharmacotherapy of Cardiovascular Disease written by Gowraganahalli Jagadeesh and published by Springer. This book was released on 2015-05-06 with total page 1323 pages. Available in PDF, EPUB and Kindle. Book excerpt: The present book covers the basic principles of cardiovascular physiology, pathophysiology and advanced pharmacology with particular emphasis on cellular mechanisms of drug action. It provides an update on the progress made in several aspects of cardiovascular diseases so that it might kindle scientists and clinicians alike in furthering basic and translational research. In addition, the book is expected to fill imperative gaps in understanding and optimally treating cardiovascular disease.
Download or read book Cardiovascular Drug Development written by Ronald D. Smith and published by . This book was released on 1984 with total page 373 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Coronary Artery Disease Therapeutics and Drug Discovery written by Miao Wang and published by Springer Nature. This book was released on 2020-04-03 with total page 345 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book provides an overview of the etiology of coronary artery disease and focuses on the main therapies and drug interventions currently available. It highlights drug pharmacology and therapeutic challenges, with a special emphasis on the underlying principles of available therapeutics and the on-going development of drugs for coronary artery disease. The book is divided into eight chapters, the first of which describes the classical mechanism of coronary artery disease and its clinical presentations. Chapter 2 lists the principles of and related evidence on the prevention and treatment of coronary artery disease. This includes diet and lifestyle management, and guidelines for the treatment of acute coronary syndrome and stable coronary artery disease. In turn, Chapter 3 describes revascularization treatments, covering percutaneous coronary interventions, coronary artery bypass grafts and thrombolysis. This chapter also addresses the main therapeutic challenges. The following chapters provide an overview of three major categories of coronary artery disease drugs, which target thrombosis (Chapter 4), lipid metabolism (Chapter 5), and hypertension (Chapter 6). Heart failure constitutes the major health burden in the late stage of coronary artery disease; accordingly, current heart failure therapeutics and related drug pharmacology are described in Chapter 7. In closing, Chapter 8 provides a summary of on-going clinical trials for coronary artery disease drug development and discusses a number of promising areas in which intensive research into new therapeutics is being pursued. Given its scope, the book will be of interest to clinicians, medical students and research scientists, as well as to pharmaceutical professionals who are seeking new therapies and drugs for coronary artery disease and related disorders.
Download or read book Cardiovascular and Metabolic Disease written by Philip Peplow and published by Royal Society of Chemistry. This book was released on 2015-05-18 with total page 396 pages. Available in PDF, EPUB and Kindle. Book excerpt: Cardiovascular and metabolic diseases remain the number one cause of death in developed countries and their prevalence is increasing rapidly in developing nations. This book brings together the recent information on these disorders and the links that exist between them in order to provide a complete picture of drug discovery for these conditions. The main three sections comprehensively discuss obesity, hypertension and cardiovascular disease, and diabetes in turn, following an introduction to the molecular links between them. The final chapter provides perspectives on future directions of the field. Chapters are contributed by leaders in the field from academia and industry and cover biomarkers, risk factors, gene-environment interactions, therapies and the various types of animal models that have been used to study each disease. Case studies describing the implementation of animal models in drug development further enhance the book’s usefulness as a comprehensive guide to this important therapeutic area. Providing a full picture of the various types of animal models that have been used to study obesity, hypertension, and insulin resistance with recent case studies, this book provides a valuable resource for medicinal chemists and clinicians working in these disease areas.
Download or read book Integrated Cardiac Safety written by J. Rick Turner and published by John Wiley & Sons. This book was released on 2008-11-26 with total page 500 pages. Available in PDF, EPUB and Kindle. Book excerpt: The serious nature of cardiovascular adverse drug reactions occurring in patients makes assessment of a drug's cardiac safety profile a high priority during both development and post-approval monitoring. Integrated Cardiac Safety provides necessary guidance and methodology for professionals assessing cardiac safety of drugs throughout all stages of the drug's life, from discovery and development through postmarketing research. This self-contained, reader-friendly text is valuable to professionals in the pharmaceutical, biotechnology, and CRO industries, pharmacologists, toxicologists, government officials, and students.
Download or read book Cardiotoxicity of Non Cardiovascular Drugs written by Giorgio Minotti and published by John Wiley & Sons. This book was released on 2010-03-25 with total page 360 pages. Available in PDF, EPUB and Kindle. Book excerpt: Some drugs which are not aimed at treating heart disease have nevertheless been found to have profound effects on heart muscle. Cardiotoxicity is one of the major forms of toxicity seen in drugs and it accounts for most drug recalls and delays experienced in regulatory approvals.In recent years a number of non-cardiac blockbuster drugs such as terfenadine have been withdrawn from major markets because of cardiotoxicity concerns, while other drugs have either been withdrawn prior to marketing or required labelling changes that significantly restricted their use. In Cardiotoxicity of Non-Cardiovascular Drugs international experts describe the molecular mechanisms and clinical read-outs of cardiac events induced by a broad variety of noncardiovascular drugs. Particular emphasis is paid to the preclinical screening of drug cardiotoxicity. Topics include: metabolic targets of cardiotoxicity regulatory aspects translating molecular mechanisms into clinical trials structure-activity relationships in arrhythmias by antihistamines and psychoactive drugs cardiovascular toxicity of antitumor drugs cardiovascular toxicities of non-steroidal anti-inflammatory drugs cardiovascular toxicities of antiretroviral therapies Cardiotoxicity of Non-Cardiovascular Drugs is an essential guide to this important area of drug development. It will find a place on the bookshelves of researchers, regulators and students in medicinal chemistry, drug development, pharmacology, pharmacy and cardiovascular disease.
Download or read book Cardiovascular Pharmacotherapeutics written by William H. Frishman, MD and published by Cardiotext Publishing. This book was released on 2011-05-11 with total page 798 pages. Available in PDF, EPUB and Kindle. Book excerpt: Everything practicing physicians and pharmacists need to know about drug therapy for cardiovascular disease. A critically acclaimed classic reference now in its third edition, Cardiovascular Pharmacotherapeutics provides current information regarding the contemporary use of all available cardiovascular medications for adults and children. Strongly emphasizing the scientific rationale behind the use of such therapies in cardiac disease, it discusses new drugs and novel compounds that are under development and may emerge as the cardiac therapies of the future. This edition also addresses special considerations for drug therapy use in the elderly, during pregnancy, and in those with hepatic or renal disease. A generous assortment of tables, figures, and appendices guides readers in their investigations of each drug group and various disease states. This new third edition presents an in-depth discussion of: All cardiovascular agents currently available The scientific basis behind every pharmacotherapy advance Mechanisms of action of cardiovascular pharmacotherapeutics The latest advances in cardiovascular drug therapy Specific drug treatments, and information on recently approved drugs Molecular biological advances Drugs in development Hands-on discussions of how to utilize specific drugs for treatment of various cardiovascular disorders and for the prevention of disease Also included are 8 appendices that provide practical, hands-on information on using drugs in clinical settings, including relevant pharmacokinetic information, and practical drug prescribing information. All updated with an accompanying website, Advances in Cardiovascular Pharmacotherapeutics www.cvpct3.com
